

November 29, 2023



Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.

**Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)
Presentation: Monday, December 4, 2023 at 3:30 pm ET
Boca Raton, FL**

A high-definition video webcast of the presentation will be available the following day on the Unicycive website under the Investors section: [Events and Presentations](#).

**2023 Benchmark Discovery One-on-One Investor Conference
December 7, 2023
New York, NY**

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit [Unicycive.com](https://unicycive.com) and follow us on [LinkedIn](#) and [YouTube](#).

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.



Source: Unicycive Therapeutics, Inc.